Pharvaris N.V. (NASDAQ:PHVS)
| Market Cap | $2.34B+41.7% |
| Revenue (ttm) | $0 |
| Net Income | -$181.84M-9.5% |
| EPS | -$2.77+5.1% |
| Shares Out | 70.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 182,582 |
| Open | $34.11 |
| Previous Close | $33.83 |
| Day's Range | $32.85 - $34.28 |
| 52-Week Range | $23.01 - $43.25 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $59.33(+77.85%) |
| Earnings Date | Apr 1, 2027 |
About PHVS
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
9 firms rating PHVS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Apr 1, 2027Earnings report
$PHVS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PHVS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PHVS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PHVS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PHVS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PHVS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PHVS
| IBBiShares Biotechnology ETF | $8.54M |
| IEFAiShares Core MSCI EAFE ETF | $4.43M |
| SCZiShares MSCI EAFE Small-Cap ETF | $2.98M |
| EWNiShares MSCI Netherlands ETF | $1.85M |
| ONEQFidelity Nasdaq Composite Index ETF | $895.34K |
| COROiShares International Country Rotation Active ETF | $691.26K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PHVS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage: positive clinical data presentation and Phase 3 momentum offset by widening Q3 losses and valuation concerns.
Recent Insider Activity
Insider Score Trend Over Time
-49.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.82% |
| FPXE | First Trust IPOX Europe Equity Opportunities ETF | 0.38% |
| EWN | iShares MSCI Netherlands ETF | 0.26% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.15% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.10% |
| IBB | iShares Biotechnology ETF | 0.08% |
| TNXT | T. Rowe Price Innovation Leaders ETF | 0.08% |
| IEUS | iShares MSCI Europe Small-Cap ETF | 0.05% |
| DBEZ | Xtrackers MSCI Eurozone Hedged Equity ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.